Changes in plasma protein binding have little clinical relevance.
about
Importance of relating efficacy measures to unbound drug concentrations for anti-infective agentsA Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDDelayed arousalThe use of toxicokinetic data in preclinical safety assessment: a toxicologic pathologist perspectiveModeling of Large Pharmacokinetic Data Using Nonlinear Mixed-Effects: A Paradigm Shift in Veterinary Pharmacology. A Case Study With Robenacoxib in CatsInfluence of alpha-1 glycoprotein acid concentrations and variants on atazanavir pharmacokinetics in HIV-infected patients included in the ANRS 107 trialDiet-induced obesity alters vincristine pharmacokinetics in blood and tissues of mice.Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladderThe 'apparent clearance' of free phenytoin in elderly vs. younger adultsIn vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.Aminoglycoside modifying enzymes.Influence of different degrees of liver impairment on the pharmacokinetics of clazosentan.Riluzole pharmacokinetics in young patients with spinal muscular atrophy.In silico prediction of human serum albumin binding for drug leads.Population pharmacokinetics of mavacoxib in osteoarthritic dogs.Diabetes and hypertension increase the placental and transcellular permeation of the lipophilic drug diazepam in pregnant women.The bioanalytical challenge of determining unbound concentration and protein binding for drugs.Immune activation mediated change in alpha-1-acid glycoprotein: impact on total and free lopinavir plasma exposure.Population analysis of weight-, age-, and sex-related differences in the pharmacokinetics of lopinavir in children from birth to 18 yearsPharmacogenomic considerations in drug delivery.Clinical implications of changes in hepatic drug metabolism in older peopleStudy on the interaction of plasma protein binding rate between edaravone and taurine in human plasma based on HPLC analysis coupled with ultrafiltration technique.Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications.Population pharmacokinetics of ceftriaxone in critically ill septic patients: a reappraisalPharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunctionDisposition and pharmacodynamics of propofol during isovolaemic haemorrhage followed by crystalloid resuscitation in humans.Clinically relevant drug interactions with antiepileptic drugs2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 - small molecules by LCMS).Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients.Population approach to analyze the pharmacokinetics of free and total lopinavir in HIV-infected pregnant women and consequences for dose adjustment.Interaction of warfarin with drugs, natural substances, and foods.Protein binding of cefazolin is saturable in vivo both between and within patientsProtein binding characteristics and pharmacokinetics of ceftriaxone in intensive care unit patientsThe pharmacokinetics and safety of darapladib in subjects with severe renal impairment.The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.Pharmacologic studies in vulnerable populations: Using the pediatric experience.Physiologically-based pharmacokinetic modeling of renally excreted antiretroviral drugs in pregnant women.Brief Report: Significant Decreases in Both Total and Unbound Lopinavir and Amprenavir Exposures During Coadministration: ACTG Protocol A5143/A5147s Results.Population pharmacokinetics of mycophenolic acid and dose optimization with limited sampling strategy in liver transplant children.
P2860
Q26827380-84AC6350-EE95-4F29-ADAC-93B3C39C56CBQ28087621-9B8E2CFF-237C-4EB1-B2BA-405F5BEB0CD4Q30477079-7F8567AF-58D6-4FEA-B99C-B994D7F4F34BQ31133421-DB87766B-00ED-4222-99C9-8690C18696DDQ31138427-1AF437AE-858D-4D12-AF8E-4F732F185629Q33348311-B84EEE9F-0B14-4D8C-A6C9-C06E10CA8C2FQ33767004-E69BEC52-E5E2-451D-A8A2-06DA8BFB60BCQ34019358-52674888-EE21-4026-AA16-BB183C7CEDCAQ34019379-85419C3B-5B7D-4C1A-9E78-1732671C731AQ34058093-737F4A6F-6E3C-4AC3-8DF8-FE3D5D1935FBQ34354185-514356DB-7CF6-477F-9A16-AC8609E8853EQ34476083-56CDC637-3126-4992-8ECA-020F514777CEQ34609016-96D65216-7773-4FC2-B0CE-0FE975A21B23Q34609144-B8DCDE6C-2C11-408A-A79D-3DCB64D38B9DQ34626223-CE01D432-83C6-439D-952D-B77906F8606EQ35019769-96EADC1C-A437-4B4A-ADB8-E9E6A87BD0BDQ35062663-BFF16771-94CF-4E4D-B2E9-FB7CA76D58BFQ35082567-83FE2E33-CA11-4D74-8499-8265ACB6080FQ35127775-426F3F2C-028B-457F-AAFB-2322E08D9F37Q35164676-C7CFDA4E-CBB7-4D78-8AEA-3B43A3362A0DQ35166691-2AA135E0-5FC9-45D9-A423-1C07DED830E5Q35534917-B2C725FD-648B-442D-860E-0C594B2DC961Q35584822-5FD092DB-48F5-47B6-ACB3-6E8F51BF0409Q35608904-5F8C2310-2921-4803-911A-2CEC71B9E9BFQ35624588-41EE61A9-6009-4687-8BC6-21317D45A384Q35819409-8332F2E7-CF20-435A-89F4-7DCD8D1086E9Q35827429-85FAC637-CFE5-4627-BCC9-710019F40B9EQ35827491-4DE3AF78-D70D-4D58-B89F-2D2B9229DB5DQ35842971-E8C3FF32-1648-4AD7-B2B4-0BC3D81166E1Q35861714-5CCA2D5A-C9E6-46CA-BBEC-ECE663FFFABBQ35960706-E584EB72-1AEC-43BD-A78D-E7722C95B207Q36007599-EF031A1E-A48B-4173-A03E-5D1199065F35Q36024418-78947FAF-F0DE-45EF-9908-2738695D7A1FQ36072500-8136DA26-044C-4EA5-A475-F547EC62FBECQ36125450-373C72E4-6C0C-41B2-AE67-AD66D4C22A5AQ36229351-2A0592B0-BAEE-4F65-8FB2-860D789A1879Q36235896-733017D0-66E9-4E23-B25D-59458BF82B7FQ36243626-EF5912C2-C10D-40A2-AD12-63883B3A0B71Q36289127-8AC9C7B2-B245-4DE1-9E8E-B07B6E94B4C8Q36336060-02F688AB-34C0-46E4-B8AC-45BA8DF252AC
P2860
Changes in plasma protein binding have little clinical relevance.
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Changes in plasma protein binding have little clinical relevance.
@ast
Changes in plasma protein binding have little clinical relevance.
@en
Changes in plasma protein binding have little clinical relevance.
@nl
type
label
Changes in plasma protein binding have little clinical relevance.
@ast
Changes in plasma protein binding have little clinical relevance.
@en
Changes in plasma protein binding have little clinical relevance.
@nl
prefLabel
Changes in plasma protein binding have little clinical relevance.
@ast
Changes in plasma protein binding have little clinical relevance.
@en
Changes in plasma protein binding have little clinical relevance.
@nl
P356
P1476
Changes in plasma protein binding have little clinical relevance.
@en
P2093
Betty-ann Hoener
Leslie Z Benet
P304
P356
10.1067/MCP.2002.121829
P407
P577
2002-03-01T00:00:00Z